Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RB1 positive |
| Therapy | Abemaciclib |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RB1 positive | triple-receptor negative breast cancer | no benefit | Abemaciclib | Phase II | Actionable | In a Phase II trial, Verzenio (abemaciclib) treatment did not meet the predetermined efficacy criteria in patients with pretreated, metastatic, RB1-positive triple negative breast cancer, resulting in an objective response rate of 0%, disease control rate of 22.2% (6/27), median progression-free survival of 1.94 months, and median overall survival of 8.44 months (PMID: 39908010; NCT03130439). | 39908010 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39908010) | A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer. | Full reference... |